Evidence map›Paper›PMID 40926299›Full record

GuidelineBritish journal of haematology2025

Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).

Xavier Cheng-Hong Tsai, Zong-Han Yao, Shu-Wei Chou, Han-Chung Hu, Yi-Chang Liu, Chia-Hung Chen, Su-Peng Yeh, Wei-Chang Huang, Tung-Liang Lin, Tsung-Ming Yang and 9 more

Abstract readConsensus StatementPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Xavier Cheng-Hong TsaiDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-4174-8766
Zong-Han YaoDepartment of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
Shu-Wei ChouDepartment of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-4562-6002
Han-Chung HuDepartment of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Yi-Chang LiuDivision of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chia-Hung ChenDivision of Pulmonary and Critical Care Medicine, China Medical University Hospital, Taichung, Taiwan.
Su-Peng YehDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Wei-Chang HuangDivision of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Tung-Liang LinDivision of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Tsung-Ming YangDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan.
Ching-Han LaiDivision of Pulmonary Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Hsin-Kuo KoDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Yao-Wen KuoDepartment of Integrated Diagnostics & Therapeutics, National Taiwan University Hospital, Taipei, Taiwan.
Hsao-Hsun HsuDepartment of Surgical Oncology and Surgery, National Taiwan University Cancer Center, Taipei, Taiwan.
Shih-Lung ChengDepartment of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan.
Chi-Cheng LiDepartment of Hematology and Oncology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.ORCID https://orcid.org/0000-0002-5022-1237
Bor-Sheng KoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-7965-7579
Hao-Chien WangDepartment of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
Taiwan Society of Blood and Marrow Transplantation and Taiwan Society of Pulmonary and Critical Care Medicine

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary chronic graft-versus-host disease (cGVHD), particularly bronchiolitis obliterans syndrome (BOS), is a severe complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT) with significant morbidity and mortality. This report, developed collaboratively by experts from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and the Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM), provides consensus statements for the diagnosis, surveillance and management of pulmonary cGVHD. Early detection through pulmonary function tests (PFTs) is critical, with serial monitoring recommended after allo-HSCT. High-resolution computed tomography (HRCT) serves as a valuable diagnostic tool, whereas bronchoalveolar lavage along with multiplex polymerase chain reaction (PCR) helps rule out infectious aetiologies. The first-line treatment approach includes inhaled and systemic corticosteroids, bronchodilators and azithromycin. The fluticasone-azithromycin-montelukast (FAM) regimen has demonstrated notable efficacy in stabilizing lung function. Emerging therapies such as ruxolitinib, belumosudil, abatacept and axatilimab offer promising benefits for refractory cases, whereas lung transplantation is a viable last resort for advanced disease. Comprehensive supportive care, encompassing pulmonary rehabilitation and infection prophylaxis, is an essential component of management. This consensus report highlights the importance of standardized PFT surveillance, early intervention and individualized immunosuppressive strategies. Future research should focus on refining diagnostic biomarkers and optimizing therapeutic approaches to improve patient outcomes.

Indexed as

Bronchiolitis ObliteransGraft vs Host DiseaseHematopoietic Stem Cell TransplantationLung DiseasesChronic DiseaseConsensusCritical CareHumansSocieties, MedicalTaiwanallogeneic haematopoietic stem cell transplantationbronchiolitis obliterans syndromeconsensusgraft‐versus‐host diseasepulmonary complication

Identifiers

PMID40926299
PMCPMC12624199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.